Talimogene laherparepvec

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

Retrieved on: 
Wednesday, August 23, 2023
Columbia University, Talimogene laherparepvec, Clinical associates, Merkel-cell carcinoma, Immunotherapy, Associate, Rutgers University, Harvard Medical School, Journal, Rush University, Translational medicine, Patient, Compass, China Bio-Immunity Corporation, Hospital, FDA, Massachusetts General Hospital, Therapy, Roswell Park Comprehensive Cancer Center, Book, Dean (education), Pharmaceutical industry, Cancer, Research

SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor.

Key Points: 
  • SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor.
  • Dr. Kaufman is a leading authority on tumor immunotherapy and oncolytic virus.
  • "We are honored to have Dr. Kaufman as our Consulting Medical Advisor, to jointly explore clinical mechanisms and translational medicine of oncolytic virus, and provide professional advice for our future clinical development.
  • said Dr. Guoying Zhou, Chairman and CEO of ImmVira, "His insights will help us accelerate global clinical progress of oncolytic virus pipelines and meet medical needs of cancer patients as soon as possible."

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

Cell Therapy Global Market Report 2022: Increasing Popularity of Stem Cell Treatments Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
General Health, Health, Stem Cells, D, Regenerative medicine, MACI, Transplant, Tissue, GVHD, Region, Cell, Autosampler, Research, Risk, USD, RepliCel, Pharmaceutical industry, Talimogene laherparepvec

The "Cell Therapy Market by Use Type, by Therapy Type, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Market by Use Type, by Therapy Type, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing popularity of stem cell therapies among end users, therapeutic benefits of these treatments over conventional medicines, and rising R&D spending in stem cell therapies are projected to drive the market growth in near future.
  • However, high price of cell therapies and a shortage of skilled workers are predicted to limit market growth are expected to restrain the market growth.
  • The market for cell therapy is being driven by the expansion of cell banking and the shift in company focus towards the creation of allogenic therapeutic solutions.

Cell Therapy Global Market Report 2022: Sector to Expand by 14.8% Annually Through 2033

Retrieved on: 
Thursday, January 26, 2023
USD, Cell, RepliCel, MACI, Region, D, Transplant, Autosampler, Risk, Regenerative medicine, GVHD, Research, Tissue, Beauty salon, Pharmaceutical industry, Talimogene laherparepvec

DUBLIN, Jan. 26, 2023 /PRNewswire/ -- The "Cell Therapy Market by Use Type, by Therapy Type, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 26, 2023 /PRNewswire/ -- The "Cell Therapy Market by Use Type, by Therapy Type, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • However, high price of cell therapies and a shortage of skilled workers are predicted to limit market growth are expected to restrain the market growth.
  • To take advantage of the untapped potential of the market for cell treatment, some companies are leading the way in developing nations including Canada.
  • The market for cell therapy is being driven by the expansion of cell banking and the shift in company focus towards the creation of allogenic therapeutic solutions.

Oncolytic Virus Cancer Therapy Market Insights, Epidemiology and Forecasts, 2019-2021 & 2022-2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Pharmaceutical, Health, Oncology, Immunotherapy, Table, Growth–share matrix, United Kingdom, Clinical trial, Radiation, SME, News, SWOT, USD, PESTLE, Comprehension, Research, Acquisition, Talimogene laherparepvec, Report, Epidemiology, Oncolytic virus, Competitive intelligence, Porter's five forces analysis, Daiichi Sankyo, Pharmaceutical industry, Health insurance, Lithium, Marketing, Amgen, Phase II

The "Oncolytic Virus Cancer Therapy - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncolytic Virus Cancer Therapy - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The Oncolytic Virus Therapies (OVTs) market report provides emerging drugs, Oncolytic Virus Therapies (OVTs) market share of the individual cancer types, current and forecasted Oncolytic Virus Therapies (OVTs) market size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current OVTs unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
  • The analysis covers Oncolytic Virus Therapies (OVTs) market uptake by drugs; patient uptake by therapies; and sales of each drug.

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

Retrieved on: 
Monday, January 10, 2022
Clinical trial, PD-1, SEC, Safety, Dexamethasone, MediGene, Immunomodulatory imide drug, Standard of care, Drug discovery, Fred Hutchinson Cancer Research Center, United States Patent and Trademark Office, Melanoma, Security (finance), Head, College of Medicine, Leadership, Patient, Cancer, Immunosuppression, Birth certificate, Immunocore, U.S. Securities and Exchange Commission, Forward-looking statement, Neoplasm, FC, Partnership, Doctor of Philosophy, Review, Research, Therapy, Private Securities Litigation Reform Act, Immunotherapy, Biomarker, Company, Risk, Nasdaq, University, University of Wales, Newport, COVID-19, GLOBE, R&D, Patent, GSK, Pharmaceutical industry, Vaccine, A2A, Talimogene laherparepvec

iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scientific officer.

Key Points: 
  • iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scientific officer.
  • I am also thrilled to announce Dr. McGraths promotion to chief scientific officer.
  • Prior to iTeos, Dr. McGrath served as the chief scientific officer at Complix N.V. and as Head of Development at Immunocore.
  • Any of the foregoing risks could materially and adversely affect iTeos business, results of operations and the trading price of iTeos common stock.

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on: 
Monday, April 19, 2021
Virotherapy, Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Akseli Hemminki, Transgene SA

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points: 
  • b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
  • Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
  • In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
  • All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on: 
Sunday, April 18, 2021
Virotherapy, Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Akseli Hemminki, Transgene SA

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points: 
  • b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
  • Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
  • In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
  • All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

Global Oncolytic Virus Therapy Immunotherapy Market USD 700 Million Opportunity

Retrieved on: 
Thursday, March 25, 2021
Health sciences, Clinical medicine, Medicine, Virotherapy, Biotechnology, Experimental cancer treatments, Oncolytic virus, Talimogene laherparepvec, Therapy, Virus, Immunotherapy, Transgene SA

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Oncolytic virus therapy constitutes of using the clinical benefits of virus for treating different diseases and specifically cancer in the pharmaceutical industry.
  • In addition, the annual growth rate set by the oncolytic virus therapy is also estimated to align the entire therapy as a self-sufficient therapy with or without combination.
  • In the research and development base for global oncolytic virus therapy, the therapy due to its widespread applications is receiving tons of investments which is however inclining the therapy market to get emerged as a therapy with numerous blockbuster products against different types of diseases.
  • In driving the entire oncolytic virus therapy at global level, there are numerous advantages that are associated with it.